论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Mascellino MT, Porowska B, De Angelis M, Oliva A
Received 6 March 2017
Accepted for publication 23 May 2017
Published 28 July 2017 Volume 2017:11 Pages 2209—2220
DOI https://doi.org/10.2147/DDDT.S136240
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr Sukesh Voruganti
Abstract: In this review, we discuss the problem of antibiotic resistance,
heteroresistance, the utility of cultures and antibiotic susceptibility tests
in Helicobacter pylori (Hp ) eradication, as well as the
updated treatment strategies for this infection. The prevalence of antibiotic
resistance is increasing all over the world, especially for metronidazole and
clarithromycin, because of their heavy use in some geographical areas.
Heteroresistance (simultaneous presence of both susceptible and resistant
strains in different sites of a single stomach) is another important issue, as
an isolate could be mistakenly considered susceptible if a single biopsy is
used for antimicrobial tests. We also examined literature data regarding
eradication success rates of culture-guided and empiric therapies. The empiric
therapy and the one based on susceptibility testing, in Hp eradication, may depend on
several factors such as concomitant diseases, the number of previous antibiotic
treatments, differences in bacterial virulence in individuals with positive or
negative cultures, together with local antibiotic resistance patterns in
real-world settings. Updated treatment strategies in Hp infection presented in the
guidelines of the Toronto Consensus Group (2016) are reported. These suggest to
prolong eradication therapy up to 14 days, replacing the old triple
therapy with a quadruple therapy based on proton pump inhibitor (PPI), bismuth,
metronidazole, and tetracycline for most of the patients, or as an alternative
quadruple therapy without bismuth, based on the use of PPI, amoxicillin,
metronidazole, and clarithromycin. The new drug vonoprazan, a first-in-class
potassium-competitive acid blocker recently approved in Japan, is also
considered to be a promising solution for Hp eradication,
even for clarithromycin-resistant strains. Furthermore, there is growing
interest in finding new therapeutic strategies, such as the development of
vaccines or the use of natural resources, including probiotics, plants, or
nutraceuticals.
Keywords: eradication,
biopsies, rescue
摘要视频链接:Helicobacter pylori resistance and updated treatment strategies